圣湘生物科技股份有限公司监事会 关于 2021 年限制性股票激励计划 首次授予部分第三个归属期及预留授予部分第二个 归属期归属名单的核查意见 圣湘生物科技股份有限公司（以下简称"公司"）监事会依据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上海证券 交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板上市公司自律 监管指南第 4 号——股权激励信息披露》等相关法律、法规及规范性文件和《圣 湘生物科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定，对公司 2021 年限制性股票激励计划（以下简称"本激励计划"）首次授予部分第三个归 属期及预留授予部分第二个归属期归属名单进行了核查，发表核查意见如下： 经核查，本激励计划首次授予的激励对象中，11 名激励对象本次因离职已不 再具备激励对象资格，2 名激励对象考核未达标，2 名首次授予激励对象因个人 原因自愿放弃本次归属。预留授予的激励对象中，2 名激励对象因离职已不再具 备激励对象资格。除上述不符合归属条件的 17 名激 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-020 （三）2021 年 10 月 22 日至 2021 年 10 月 31 日，公司对本激励计划首次授予激 励对象的姓名和职务在公司内部进行了公示。在公示期内，公司监事会未收到与本激 励计划首次授予激励对象有关的任何异议。2021 年 11 月 3 日，公司于上海证券交易 所网站（www.sse.com.cn）披露了《监事会关于公司 2021 年限制性股票激励计划首次 授予激励对象名单的审核意见及公示情况说明》。 （四）2021 年 11 月 15 日，公司召开 2021 年第三次临时股东大会，审议并通过 了《关于<公司 2021 年限制性股票激励计划（草案）>及其摘要的议案》《关于<公司 2021 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董 事会办理公司股权激励计划相关事宜的议案》。同时，公司就内幕信息知情人在《圣湘 生物科技股份有限公司 2021 年限制性股票激励计划（草案）》（以下简称"《激励计划 （草案）》"）公开披露前 6 个月内买卖公司股票的情况进行了自查，未发现利用内幕 信息进行股票交易的情形。202 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 证券代码：688289 证券简称：圣湘生物 公告编号：2025-019 圣湘生物科技股份有限公司 关于 2021 年限制性股票激励计划首次授予部分 第三个归属期及预留授予部分第二个归属期符合 归属条件的公告 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 限制性股票拟归属数量：456,392 股 归属股票来源：圣湘生物科技股份有限公司（以下简称"公司"）从二级市场回 购的公司人民币 A 股普通股股票。 一、本次股权激励计划批准及实施情况 （一）本次股权激励计划方案及履行的程序 1、本次股权激励计划主要内容 （1）股权激励方式：第二类限制性股票。 （2）授予数量（调整后）：公司 2021 年限制性股票激励计划（以下简称"本激励 计划"）授予的限制性股票总量为 666.00 万股，其中首次授予限制性股票 585.784 万 股，预留授予限制性股票 80.216 万股。 （3）授予价格（调整后）：首次授予价格 14.12 元/股，预留授予价格 12.49 元/股。 （4）激励人数：首次授予 151 人，预留授予 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-018 圣湘生物科技股份有限公司 关于调整 2021 年限制性股票激励计划授予价格 的公告 圣湘生物科技股份有限公司（以下简称"公司"）于 2025 年 3 月 7 日召开第二届 董事会 2025 年第四次临时会议及第二届监事会 2025 年第二次临时会议，审议通过了 《关于调整 2021 年限制性股票激励计划授予价格的议案》，董事会同意将公司 2021 年限制性股票激励计划（以下简称"本激励计划"）首次授予价格由 14.57 元/股调整为 14.12 元/股，预留授予价格由 12.94 元/股调整为 12.49 元/股，现将有关事项说明如下： 一、本激励计划已履行的决策程序和信息披露情况 （一）2021 年 10 月 21 日，公司召开第一届董事会 2021 年第八次临时会议，审 议通过了《关于<公司 2021 年限制性股票激励计划（草案）>及其摘要的议案》《关于 <公司 2021 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提请股东 大会授权董事会办理公司股权激励计划相关事宜的议案》等议案。公司独立董事就本 激励计划相关议案发表了 ...

湖南启元律师事务所 关于圣湘生物科技股份有限公司 2021 年限制性股票激励计划授予价格调整、首次授予 部分第三个归属期及预留授予部分第二个归属期归 属条件成就及部分限制性股票作废的法律意见书 2025 年 03 月 1 致：圣湘生物科技股份有限公司 湖南启元律师事务所（以下简称"本所"）接受圣湘生物科技股份有限公司（以 下简称"公司""圣湘生物"）的委托，作为公司2021年限制性股票激励计划项 目（以下简称"本次激励计划""激励计划"）专项法律顾问为公司本次激励计 划提供专项法律服务。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）及中国证券监督管理委员会 （以下简称"中国证监会"）发布的《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、上海证券交易所发布的《科创板上市公司自律监管指南第 4号——股权激励信息披露》（以下简称"《披露指南》"）、《上海证券交易 所科创板股票上市规则》（以下简称"《上市规则》"）等现行法律、法规和规 范性文件以及《圣湘生物科技股份有限公司公司章程》（以下简称"《公司章程》"） 的有关规定，按照律师行 ...

Group 1 - The government work report emphasizes shifting economic policies towards improving people's livelihoods and promoting consumption, aiming to boost economic circulation and upgrade industries through consumption [1] - The chairman of Shengxiang Biotechnology, Dai Lizhong, highlights the importance of personalized treatment solutions and digital empowerment in healthcare to enhance disease treatment, prevention, and health management [1][2] - The health consumption market in China is expected to experience significant growth, driven by increasing demand for health-related services and products, particularly in the context of an aging population [2] Group 2 - There is a current mismatch in the health consumption sector, with a concentration on health products and beauty services, while high-quality products and services for disease prevention and personalized healthcare are lacking [2] - Recommendations include incorporating health consumption into national consumption promotion policies, enhancing life science innovation, and improving policy and financial support systems to accelerate the growth of the life science industry [2] - The global life science industry is undergoing a technological revolution, presenting opportunities for Chinese companies to expand internationally, with a focus on "technology + service" output [3]

证券研究报告 2025 年 02 月 27 日 湘财证券研究所 公司研究 圣湘生物（688289.SH）事件点评 收购红岸基元进军血球检测，全生态产业链布局持续完善 相关研究： 核心要点： 拟以自有资金通过股权转让及增资的方式，收购红岸基元 54%的股权 2025 年 2 月 26 日，圣湘生物发布公告，公司拟与关联方湖南湘江圣湘生 物产业基金合伙企业（有限合伙）及湖南圣维星耀企业咨询合伙企业（有 限合伙）共同投资长沙市红岸基元生物科技有限公司。其中，公司以自有 资金合计投资 7,560 万元，通过受让股权及增资交易后，将持有目标公司 54%的股权。截至 2024 年 12 月 31 日，红岸基元资产总额 1,470.20 万 元，负债总额 2,176.17 万元，资产净额-705.97 万元；2024 年度实现营业 收入 3,270.18 万元，净利润-1,284.06 万元。 红岸基元专注雪球 POCT 领域，业务处于快速拓展期间 红岸基元成立于 2022 年 7 月，专注血球仪 POCT 的生产及销售。红岸基元 采用"图像法（高速相机拍照+AI 算法）"的方法学，开发了五分类血球仪 POCT 等产品。根 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Viewpoints - The company plans to acquire 54% of Hong'an Jiyuan's equity through self-funding, enhancing its blood cell detection capabilities and expanding its ecosystem [1] - Hong'an Jiyuan focuses on the production and sales of blood cell analyzers in the POCT field, with a strong growth trajectory and established supply chain [2] - The company has ample cash reserves exceeding 4.5 billion, indicating a proactive approach to external exploration and development [3] - Revenue projections for 2024-2026 are set at 1.445 billion, 1.959 billion, and 2.491 billion respectively, with net profits of 315 million, 459 million, and 626 million [4] Summary by Sections Acquisition Details - The company will invest a total of 75.6 million to acquire 54% of Hong'an Jiyuan, which had total assets of 14.702 million and a net profit of -12.8406 million for 2024 [1] Business Expansion - Hong'an Jiyuan, established in July 2022, is rapidly expanding in the blood cell analyzer market, targeting low penetration rates in community health centers and clinics [2] - The company has developed a systematic supply chain and sales team, achieving significant installations of blood cell analyzers across multiple provinces since its product launch in 2024 [2] Financial Position - As of Q3 2024, the company holds over 4.5 billion in cash and financial assets, indicating strong liquidity for future investments [3] - The company has been actively acquiring stakes in various technology platforms since 2021, including gene sequencing and chemiluminescence [3] Financial Forecast - Revenue and net profit forecasts for 2024-2026 are maintained at 1.445 billion, 1.959 billion, and 2.491 billion for revenue, and 315 million, 459 million, and 626 million for net profit respectively [4]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, focusing on innovation, overseas expansion, thematic investments, and dividend strategies as the main investment themes [2][17]. Core Insights - The pharmaceutical sector experienced a short-term pullback but remains optimistic about the innovation-driven growth trajectory. Key areas of focus include innovative drugs, international market expansion, and supportive policies for innovation [2][17]. - The report highlights the importance of innovative drugs as a new productive force, with significant policy support expected to accelerate their development [17]. - The report emphasizes the potential of companies with strong clinical pipelines and innovative capabilities, particularly in the context of recent supportive policies for innovative drugs [16][17]. Summary by Sections Current Industry Investment Strategy - The pharmaceutical index fell by 2.72% in the week, underperforming the CSI 300 index by 1.97 percentage points. Year-to-date, the sector has risen by 1.11%, outperforming the CSI 300 by 1.75 percentage points [15]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 26.53 times, with a premium of 75.91% relative to the entire A-share market [15]. Key Companies and Their Performance - **Hengrui Medicine**: Recent updates on lung cancer data show promising results, with an overall response rate (ORR) of 73% and median progression-free survival (mPFS) of 11.5 months, indicating strong commercial potential [16]. - **Innovative Drug Policies**: New policies are expected to encourage commercial insurance companies to invest in innovative drug companies and improve pricing standards [16][17]. Thematic Investment Lines - **Innovation and Overseas Expansion**: The report identifies innovative drugs as a key area, with a high success rate in recent insurance negotiations for innovative drugs [17]. - **Dividend Strategy**: With the 10-year government bond yield falling below 2%, dividend-paying assets with stable growth and cash flow are highlighted as defensive and offensive investment options [9][18]. Recommended Investment Combinations - The report lists several recommended stocks, including Hengrui Medicine, Enhua Pharmaceutical, and Yifan Pharmaceutical, among others, indicating a strong buy rating for these companies based on their growth potential and market performance [19][22].

Financial Performance - The total operating revenue for 2024 reached CNY 1.496 billion, representing a year-on-year increase of 48.60%[5] - The net profit attributable to the parent company was CNY 259.03 million, a decrease of 28.78% compared to the previous year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses increased by 194.13% to CNY 210.74 million[3] - The basic earnings per share decreased by 29.03% to CNY 0.44[3] - The company's total assets increased by 2.12% to CNY 8.634 billion[3] - The company reported a decrease in investment income compared to the previous year, impacting overall profit contributions[6] Product Development and Innovation - The company successfully developed a "Smart Control Platform for Infectious Diseases," integrating IoT, cloud computing, big data, and AI technologies[5] - The respiratory product revenue doubled compared to the previous year, becoming a key driver of growth[5] - The company launched dozens of innovative products across key areas such as respiratory, gene sequencing, and immunology[5] Strategic Collaborations - The company is enhancing strategic collaborations with partners like QuantuMDx and First Light to improve product matrix and commercialization efficiency[6]